Table 4.
Multivariate analysis: overall survival and local-regional progression-free survival
|
Variable |
OS |
LRPFS |
||||
|---|---|---|---|---|---|---|
| p | HR | 95% CI | p | HR | 95% CI | |
| Gender (Female vs. Male) |
0.288 |
0.802 |
0.534-1.205 |
0.278 |
0.753 |
0.450-1.258 |
| Age (years) (≥65 vs. <65) |
0.297 |
0.817 |
0.558-1.195 |
0.248 |
0.760 |
0.477-1.211 |
| Pathological type (Non-squamous vs. Squamous) |
0.106 |
1.364 |
0.936-1.988 |
0.494 |
1.184 |
0.729-1.924 |
| T stage (T3-T4 vs. T1-T2) |
0.728 |
1.067 |
0.740-1.540 |
0.702 |
1.097 |
0.684-1.759 |
| Distant metastatic lesions (No radiotherapy vs. Radiotherapy) |
0.682 |
1.083 |
0.740-1.584 |
0.652 |
1.118 |
0.689-1.812 |
| Intrathoracic primary tumors (No response vs. Response) |
0.592 |
1.124 |
0.733-1.724 |
0.581 |
1.188 |
0.644-2.190 |
| GTV (<175 cm3 vs. ≥175 cm3) |
0.008 |
1.747 |
1.153-2.646 |
0.003 |
2.321 |
1.336-4.032 |
| Post-treatment KPS (Decreased ≥10 vs. Stable or increased ≥10) |
0.000 |
6.282 |
3.568-11.058 |
0.000 |
8.038 |
3.769-17.140 |
| N stage (N2-N3vs. N0-N1) |
0.059 |
1.636 |
0.981-2.727 |
0.234 |
1.438 |
0.790-2.615 |
| Chemotherapy cycles (2–3 vs. 4–5) |
0.035 |
1.484 |
1.028-2.144 |
0.128 |
1.431 |
0.903-2.268 |
| Intrathoracic primary tumors radiation doses (<63Gy vs. ≥63Gy) | 0.057 | 1.433 | 0.989-2.075 | 0.051 | 1.562 | 0.999-2.443 |